Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20382914 | 0.92 | TLR7 (0.33) | KDM4EMAPTALDH1A1GAAHTT | |
| SCHEMBL15918975 | 0.81 | PDE10A (0.36) | L3MBTL1IKBKBNUDT1 | |
| SCHEMBL21986320 | 0.78 | L3MBTL1 (0.34) | L3MBTL1IKBKB | |
| SCHEMBL2480217 | 0.78 | NUDT1 (0.47) | NUDT1 | |
| SCHEMBL2180681 | 0.78 | GRIN2D (0.33) | CCNE2CCNE1CDK2L3MBTL1IKBKB | |
| SCHEMBL14381040 | 0.77 | TLR7 (0.33) | — | |
| SCHEMBL19554107 | 0.76 | MYC (0.38) | SSTR4L3MBTL1KDM4EMAPTALDH1A1 | |
| SCHEMBL15061729 | 0.73 | TLR7 (0.32) | — | |
| SCHEMBL22337979 | 0.73 | SSTR4 (0.39) | SSTR4CCNE2CCNE1CDK2IKBKB | |
| SCHEMBL8240025 | 0.73 | TLR7 (0.53) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| EP-2193131-B1 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| EP-2193131-A2 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | Biofocus DPI Limited (GB) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | SSTR4 2078/4885CCNE2 1676/4885CCNE1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.